| Dr Steven J Nierenberg, MD | |
|
2422 S Broad St, 1st Floor, Phila, PA 19145-4418 | |
| (215) 389-0607 | |
| (215) 389-0604 |
| Full Name | Dr Steven J Nierenberg |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 42 Years |
| Location | 2422 S Broad St, Phila, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245215136 | NPI | - | NPPES |
| 0011272000011 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD034592E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Jefferson University Hospital | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Associates In Healthcare, Inc | 6406755651 | 264 |
| Jefferson University Physicians | 7911819180 | 1269 |
News Archive
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
A staggering 35% of US entrepreneurs suffer from dyslexia, compared to 20% in the UK, a ground-breaking study by Julie Logan, Professor of Entrepreneurship at Cass Business School, reveals.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient's pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
› Verified 6 days ago
| Entity Name | Jefferson University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326093675 PECOS PAC ID: 7911819180 Enrollment ID: O20040225000232 |
News Archive
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
A staggering 35% of US entrepreneurs suffer from dyslexia, compared to 20% in the UK, a ground-breaking study by Julie Logan, Professor of Entrepreneurship at Cass Business School, reveals.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient's pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
› Verified 6 days ago
| Entity Name | Methodist Associates In Healthcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053355131 PECOS PAC ID: 6406755651 Enrollment ID: O20040402000835 |
News Archive
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
A staggering 35% of US entrepreneurs suffer from dyslexia, compared to 20% in the UK, a ground-breaking study by Julie Logan, Professor of Entrepreneurship at Cass Business School, reveals.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient's pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven J Nierenberg, MD 2422 S Broad St, 1st Floor, Phila, PA 19145-4418 Ph: (215) 389-0607 | Dr Steven J Nierenberg, MD 2422 S Broad St, 1st Floor, Phila, PA 19145-4418 Ph: (215) 389-0607 |
News Archive
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
A staggering 35% of US entrepreneurs suffer from dyslexia, compared to 20% in the UK, a ground-breaking study by Julie Logan, Professor of Entrepreneurship at Cass Business School, reveals.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient's pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
› Verified 6 days ago
Dr. Robert Shore, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 7602 Central Ave, Stapeley Bldg Suite 101, Phila, PA 19111 Phone: 215-969-2900 Fax: 215-969-1856 | |
Christopher James Adkins, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 132 S. 10th Street, 480 Main Building, Phila, PA 19107 Phone: 215-955-8900 Fax: 215-955-5245 | |
Dr. Thomas J Scheuerman, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1411 Wolf St, Phila, PA 19145 Phone: 215-334-8780 Fax: 215-334-1086 | |
Ruchika Patel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5501 Old York Rd, Korman Bldg Suite 103, Phila, PA 19141 Phone: 215-456-7380 Fax: 215-456-3898 | |
Dr. Efua Asamoah-odei, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 227 N Broad St Ste 301, Phila, PA 19107 Phone: 215-762-7785 Fax: 215-568-6007 | |
Ivan Rudolph, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 132 S 10th St, 480 Main Building, Phila, PA 19107 Phone: 215-955-8900 Fax: 215-955-5245 | |
Dr. Remigio Victor Boccio, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3900 Woodland Ave, Gen Med-111, Phila, PA 19104 Phone: 215-823-4133 |